CHOLINESTERASE INHIBITORS AND THE RISK OF PULMONARY DISORDERS IN HOSPITALIZED DEMENTIA PATIENTS
Main Article Content
Keywords
Cholinesterase inhibitor, pulmonary disorders, dementia, Alzheimer
Abstract
Objective
To evaluate whether Cholinesterase inhibitors (ChEI) are associated with an increased risk of pulmonary disorders (PD) in hospitalized dementia patients.
Methods
We conducted an observational cross-sectional study by examining the medical records of all the dementia patients hospitalized in the acute geriatric ward at the Bertinot Juel Hospital between January 1, 2005 and June 30, 2009. First, we examined whether there were any differences between the patients receiving ChEIs and those who were not. Second, we measured whether the patients had any type of PD outcome, including pneumonia, persistent cough, bronchitis, and asthma. Finally, we studied the association between ChEIs and PD. We used a logistic regression analysis preceded by a univariate analysis to adjust for other variables, such as age, weight, severity of dementia, length of stay in hospital, and history of asthma.
Results
The study included 183 patients with a mean age of 83 years. There were 131 females and 52 males. There were 55 patients with PD, including 37 with pneumonia, 11 with bronchitis, 4 with asthma, 2 with acute respiratory failure and 1 with a persistent cough. In 38 of these cases, the PD was present before hospitalization and was considered the cause of hospitalization. In 17 cases, the PD was not present at admission but occurred during hospitalization. Only ChEI treatment and age (> 80 years) were associated with an increased risk of pulmonary disorders. The adjusted relative risk was 1.98 [1.21, 3.23] for ChEI and 1.30 [1.10, 1.54] for age.
Conclusion
When prescribing ChEIs, physicians should be aware about the risk of PD. As well, withdrawing ChEIs in patients who present repeated PD should be discussed. Prospective studies need to be conducted to confirm our findings.
References
2. Sener S, Ozsarac M. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J 2006 Jan;23(1):82-5.
3. Taylor AM, Hoehns JD, Anderson DM, Tobert DG. Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother 2002 Oct;36(10):1550-3.
4. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001 Dec;49(12):1590-9.
5. Winblad B, Engedal K, Soininen H, et al. A 1- year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14;57(3):489-95.
6. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004 Sep-Oct;12(5):473-82.
7. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003 Nov;10(6):633-40.
8. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry 2008 Feb;23(2): 207-14.
9. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004 Feb;61(2): 252-6.
10. Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004 Nov;11(11): 734-41.
11. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11;158(9):1021-31.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998 Jan;50(1):136-45.
13. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14;57(3):481-8.
14. Fuschillo C, Ascoli E, Franzese G, et al. Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. Arch Gerontol Geriatr Suppl 2004;(9):187-94.
15. Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009 Mar;119(3):180-5. Epub 2008 Aug 26.
16. Farlow MR, Lilly ML; ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005 Jan 19;5:3.
17. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004 Nov;20(11):1747-52.
18. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005 Aug;21(8): 1317-27.
19. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21(5-6):353- 63. Epub February 27, 2006.
20. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 2004 Jul-Aug;12(4):420-31.
21. Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52- week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord 2009;27(3):232-9. Epub 2009 Feb 25.
22. Griffith P, Lichtenberg P, Goldman R, Payne- Parrish J. Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease. J Natl Med Assoc 2006 Oct;98(10):1590-7.
23. Mossello E, Tonon E, Caleri V, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Archives of Gerontology and Geriatrics 2004(9):297-307.
24. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004 Fall;11(2):e274-85. Epub Dec 15, 2004.
25. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001 Sep;16(9):852-7.
26. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005 Jul;61(5-6):361-8. Epub May 24, 2005.
27. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004 Jun 26;363(9427):2105-15.
28. Doody RS, GeldmChEIr DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001 Mar;58(3):427-33.